From: An economic analysis of poliovirus risk management policy options for 2013–2052
Model input | Base Case Value | Source | |||
---|---|---|---|---|---|
Low-income country | Lower middle-income country | Upper middle-income country | High-income country | ||
Vaccine price per dose | |||||
- OPV (any formulation) | $ 0.12 | $ 0.12 | $ 0.13 | $ 0.16 | |
- IPV (10-dose vial) | $ 1.30 | $ 2.30 | $ 3.20 | $ 13.00 | |
Effective vaccine wastage | |||||
- OPV in RI | 50 % | 50 % | 30 % | 10 % | |
- OPV or IPV in SIAs | 44 % | 44 % | 44 % | 44 % | |
- IPV (10-dose vial) | 40%a | 40%a | 30 % or 25%a | 10 % or 5%a | |
Administration costs per dose | |||||
- OPV in RI | $ 0.86 | $ 0.86 | $ 2.29 | $ 2.90 | |
- OPV co-administered in RIb | $ 0.30 | $ 0.30 | N/A | N/A | |
- OPV in pSIAs | $ 0.60 | $ 0.60 | $ 3.30 | $ 4.20 | |
- OPV in oSIAsc | $ 0.90 | $ 0.90 | $ 4.95 | $ 6.30 | |
- IPV single antigen in RI | $ 1.08 | $ 1.08 | $ 2.86 | $ 10.36 | |
- IPV combo in RI | N/A | N/A | $ 0.72 | $ 2.59 | |
Treatment costs per paralytic polio case | $ 650 | $ 6,500 | $ 65,000 | $ 650,000 | |
Disability-adjusted life-years per paralytic polio case | 13 | 14 | 14 | 14 | |
Societal economic costs per paralytic polio cased | $ 7,800 | $ 27,000 | $ 96,000 | $ 550,000 |